92 varieties are on display!

The latest data from Minet.
com shows that the sales of more than 500 varieties of chemical drug terminals in public hospitals in key provinces and cities will exceed 100 million yuan in 2021, and 92 of them will have a sales growth rate of more than 50%.
And new products are approved to drive market expansion
.

The total sales of 92 varieties exceeded 20 billion yuan, and the annual sales of 10 varieties exceeded 500 million yuan; the sales of 47 varieties doubled, and the sales of 2 exclusive varieties soared more than 400 times

In 2021, the chemical drug terminal sales of public hospitals in key provinces and cities will exceed 100 million and the growth rate will exceed 50%.

Source: Terminal competition pattern of public hospitals in key provinces and cities of Minet

92 varieties cover 13 therapeutic categories, focusing on anti-tumor and immunomodulatory agents (20 varieties), digestive system and metabolic drugs (17 varieties), cardiovascular and cerebrovascular drugs (11 varieties) and blood and hematopoietic systems Drugs (11 varieties)
.

Judging from the inclusion of medical insurance, 80 varieties belong to the 2021 version of the National Medical Insurance Catalogue (68 are Category B), accounting for about 87%

More than 40 varieties are exclusive varieties (calculated by drug name, including exclusive dosage forms), of which Novartis, Merck, BeiGene, Hengrui Medicine, Roche, Novo Nordisk and other companies have two or more varieties listed
.

The market exceeds 20 billion yuan, and the sales of 10 varieties exceed 500 million yuan

The market exceeds 20 billion yuan, and the sales of 10 varieties exceed 500 million yuan

In terms of sales, the total market size of 92 types of public hospitals in key provinces and cities will exceed 20 billion yuan in 2021, a year-on-year increase of 116.
8%
.

The sales of 10 varieties exceeded 500 million yuan, including Pertuzumab Injection (Roche), Ilaprazole Sodium for Injection (Livzon), Camrelizumab for Injection (Hengrui), Sacuba Trivalsartan Sodium Tablets (Novartis), Alectinib Hydrochloride Capsules (Roche), Sintilimab Injection (Cinda) and other exclusive varieties
.

In 2021, the terminal sales of public hospitals in key provinces and cities will exceed 500 million varieties with a growth rate of more than 50%

Source: Terminal competition pattern of public hospitals in key provinces and cities of Minet

Pertuzumab injection led the way with sales of nearly 1 billion yuan.
This is a new type of anti-HER2 drug developed by Roche, which produces anti-HER2 effect by inhibiting HER2 heterologous and homodimers.
It was approved for import in June for the adjuvant treatment of patients with HER2-positive early breast cancer
.

The product was included in the national medical insurance through negotiation in 2019, and began to rapidly increase in volume in 2020, with a sales growth rate of more than 2,000%, and a year-on-year increase of nearly 100% in 2021

Sales of terminal Pertuzumab injection in public hospitals in key provinces and cities (unit: 10,000 yuan)

Source: Terminal competition pattern of public hospitals in key provinces and cities of Minet

Ilaprazole is an irreversible proton pump inhibitor that inhibits gastric acid secretion by inhibiting H+, K+-ATPase, and is clinically used to treat duodenal ulcers
.

At present, the main dosage forms of ilaprazole that have been listed in China are enteric-coated tablets and injections, and there is only one manufacturer of Livzon

Sales of ilaprazole sodium for injection in public hospitals in key provinces and cities (unit: 10,000 yuan)

Source: Terminal competition pattern of public hospitals in key provinces and cities of Minet

Sacubitril-Valsartan is a compound preparation consisting of sacubitril (enkephalinase inhibitor) and valsartan (angiotensin receptor antagonist).
In 2018, it was included in the national medical insurance through negotiation, and the sales growth rate in the past three years has reached triple digits
.

At present, more than 10 generic drugs from Kelun, Nanjing Chia Tai Tianqing, Qilu, Shijiazhuang and other companies have submitted marketing applications.

Sales of sacubitril and valsartan sodium tablets in public hospitals in key provinces and cities (unit: 10,000 yuan)

Source: Terminal competition pattern of public hospitals in key provinces and cities of Minet

The sales of 47 varieties doubled, and the 2 exclusive varieties soared more than 400 times

The sales of 47 varieties doubled, and the 2 exclusive varieties soared more than 400 times

In terms of growth rate, the sales growth rate of 47 varieties in 2021 will exceed 100%, of which 8 varieties will soar by more than 1000%, edaravone dexbornol injection concentrated solution and dupilimumab injection will soar by more than 1,000%.
400 times
.

In 2021, the terminal sales of public hospitals in key provinces and cities will exceed 100 million varieties with a growth rate of over 100 million

Source: Terminal competition pattern of public hospitals in key provinces and cities of Minet

The concentrated solution of edaravone and dexbornol for injection is a new class 1 drug in the field of cerebrovascular disease independently developed by Simcere Pharmaceuticals.
It is a scientific combination of edaravone and dexbornol in a 4:1 ratio.
The ingredients have multiple mechanisms of scavenging free radicals, anti-inflammatory and protecting the blood-brain barrier, which can significantly reduce the brain nerve damage caused by acute ischemic stroke
.

The product was approved for marketing in July 2020, and was included in the national medical insurance through negotiation in the same year, and sales in 2021 will soar nearly 600 times

Sales of edaravone dexbornol injection concentrated solution in public hospitals in key provinces and cities (unit: 10,000 yuan)

Source: Terminal competition pattern of public hospitals in key provinces and cities of Minet

Dupilimumab injection is a fully human monoclonal antibody jointly developed by Sanofi and Regeneron.
By blocking the downstream signal transduction of IL-4 and IL-13, the relief is mainly mediated by Th2 cells.
diseases, including atopic dermatitis, asthma, allergic rhinitis,
etc.

The product was included in the second batch of overseas new drugs urgently needed for clinical use, and was approved for import in June 2020

Sales of terminal dupriumab injection in public hospitals in key provinces and cities (unit: 10,000 yuan)

Source: Terminal competition pattern of public hospitals in key provinces and cities of Minet

Eli Lilly's olanzapine orally disintegrating tablets were approved for import very early, and generic drugs from Qilu, Hansoh, and Sunshine Pharmaceuticals were successively approved for production in 2019
.

This variety was included in the third batch of centralized procurement, and a number of "barefoot" enterprises were selected for centralized procurement and rapidly increased the volume, driving the sales of the entire variety to surge, with a year-on-year increase of more than 3,000% in 2021

Sales of terminal olanzapine orally disintegrating tablets in public hospitals in key provinces and cities (unit: ten thousand yuan)

Source: Terminal competition pattern of public hospitals in key provinces and cities of Minet

Domestic innovative drugs are rapidly increasing in volume, and centralized procurement varieties meet the challenges

Domestic innovative drugs are rapidly increasing in volume, and centralized procurement varieties meet the challenges

Medical insurance and centralized procurement are two major policies that affect the terminal drug pattern of public hospitals, forcing enterprises to transform into R&D innovation
.

Some of the 92 varieties of domestic class 1 new drugs

Source: Terminal competition pattern of public hospitals in key provinces and cities of Minet

Driven by medical insurance, many domestic innovative drugs have seen rapid volume growth after they are launched, such as ametinib mesylate tablets (Hassen), edaravone dexbornol injection concentrated solution (first approved for marketing in 2020) (BeiGene), Tislelizumab Injection (BeiGene), and Zanubrutinib Capsules (BeiGene) were all included in the national medical insurance through negotiation in the same year, and the sales growth in 2021 will all reach 4 digits or more
.

Collected varieties of 92 varieties (including those to be included)

Source: Terminal competition pattern of public hospitals in key provinces and cities of Minet

Centralized procurement mainly affects varieties in mature markets, and the market size of related varieties has declined due to sharp price reductions.
For example, oxaliplatin injection included in the fifth batch of centralized procurement is expected to sell oxaliplatin injection in public hospitals in 2022.
The scale will drop sharply
.

For generic drugs that have been approved late and the market has not yet opened, "barefoot" companies can instead rely on centralized procurement to quickly increase the volume of the entire variety, such as the third batch of olanzapine orally disintegrating tablets
.